MJM98
Posted - 2 days ago
$ASND druck adding
Rmimidear
Posted - 3 days ago
$ASND Ascendis Pharma’s advancements in endocrinology and oncology treatments keep it as a leader in biotech innovation!
JFDI
Posted - 5 days ago
$ASND Weekly base Druckenmiller name
JFDI
Posted - 5 days ago
$ASND look at that monthly.
ohkanby
Posted - 5 days ago
$ASND I wonder if this price action is a result of the ER or the U.S. pharma industry getting rocked
Pika_Capital
Posted - 5 days ago
$ASND it's beyond me how 🤡 s on here get >10k watchers 😂
OpenOutcrier
Posted - 5 days ago
$ASND (-1.3% pre) Ascendis Pharma Reports Revenue Growth Despite Loss - tr https://ooc.bz/l/48308
ohkanby
Posted - 6 days ago
$ASND so when is Novo Nordisk gonna acquire Ascendis. They doing that dance that biotechs do just before.
Pika_Capital
Posted - 6 days ago
$ASND that price is longgg.gone. Some scared ass 🤡 unloaded his position
1986iamwallstreet
Posted - 6 days ago
$ASND 103 after hours lows …..
DonCorleone77
Posted - 6 days ago
$ASND Ascendis Pharma reports Q3 EPS (EUR 1.72) vs. (EUR 2.88) last year Reports Q3 revenue EUR 57.84M vs. EUR 48.03M last year. "2024 has been another transformative year for Ascendis. Now, all three of our three endocrinology rare disease programs have delivered clinically differentiated pivotal data, each demonstrating potential ability to address major unmet medical needs and the potential for each to achieve blockbuster status. We are ready and very excited about launching YORVIPATH in the U.S. with product availability expected in mid-January of 2025," said Jan Mikkelsen, Ascendis Pharma's President and Chief Executive Officer. "In addition, our new partnership with Novo Nordisk highlights our ability to extend the success of our TransCon platform and positions Ascendis to benefit patients and capture significant value in this large, high volume therapeutic areas."
1986iamwallstreet
Posted - 6 days ago
$ASND let’s see 70 …..
Estimize
Posted - 6 days ago
$ASND reports after the close, Estimize Consensus -0.03 EPS and -4.02M Revs compared to WS
http://www.estimize.com/asnd/fq3-2024?utm_conten
ChessGM
Posted - 1 week ago
$ASND Heads up alert! Only one day until Upcoming earnings on Thursday, 11/14/2024 for $ASND Bullish (7.5) Ascendis Pharma A/S (NASDAQ: ASND) has demonstrated a positive trajectory recently, particularly with its strategic collaboration with Novo Nordisk, which emphasizes the licensing of its TransCon technology. This partnership is expected to generate up to $285 million in milestone payments, alongside sales-based royalties. The development of a once-monthly GLP-1 receptor agonist for obesity and type 2 diabetes aligns with growing market demands for innovative therapies in these areas. Financially, Ascendis shows a promising outlook, highlighted by an EPS of $1.32 and a P/E ratio of 25.4, which, while slightly above the industry average, reflects investor confidence in its growth potential. Revenue forecasts for the upcoming fiscal year indicate a robust increase, positioning the company favorably against industry peers, particularly in the burgeoning biopharmaceutical sector. The recent submission of a supplemental Biologics License Application (sBLA) for TransCon hGH indicates proactive steps towards expanding its product offerings, which could enhance its market position significantly in the coming quarters. Regarding upcoming earnings reports, Ascendis Pharma is set to release its third-quarter 2024 financial results on November 14, 2024. Historical performance has shown a steady revenue growth, with analysts projecting an increase in earnings per share (EPS) by approximately 10% year-over-year. The consensus estimate for the upcoming quarter stands at $0.34 EPS, reflecting strong anticipated performance driven by recent product developments and partnerships. Given the favorable comparisons with its peers and the potential for additional revenue streams from the Novo Nordisk collaboration, the forthcoming earnings report could serve as a significant catalyst for the stock, potentially driving further investor interest and market valuation. - Funds were net buyers of $ASND during the previous reporting quarter. - Here are some of the funds with a sizable holdings (as of Q3 of 2024) for $ASND: * RA Capital Management LLC $1,379MM. New position. CGMFundRank: 62%, Fund Website: www.racap.com * Westfield Capital Management Company LP $677MM. New position. CGMFundRank: 83%, Fund Website: www.westfieldcapital.com * Avoro Capital Advisors LLC $572MM. New position. CGMFundRank: 83%, Fund Website: avorocapital.com * Adage Capital P $112MM. New position. CGMFundRank: 88%, Fund Website: www.adagecapital.com * Paradigm Biocap $91MM. New position. CGMFundRank: 55% - Last 10 days performance: 2% - Last 30 days performance: -1% - Last 90 days performance: -8% Follow ChessGM on stocktwits.com to get timely earnings alerts. Not a financial advice. Not a trading signal.
Night_Owl_Biotech
Posted - 2 weeks ago
$KALV announced a royalty financing with DRI on its sebetralstat therapy for HAE with a 6/17/2025 PDUFA date. DRI committed $100MM in exchange for a 5% royalty on sebetralstat sales. Using simple math, this transaction by itself suggests a $2.0B sebetralstat valuation. KALV's market cap is just under $500MM. This is not investment advice because this simple comparison has many flaws & does not consider dozens of other valuation considerations. More important, if the FDA does not approve sebetralstat then KALV could go bankrupt & shareholders could lose 100% of their investment. The attachment compares the KALV/DRI royalty financing agreement with peer transactions of FDA approved therapies (though $IBRX & $VRNA therapies were not approved at the time of their respective agreements). Please let us know if we are missing any FY2024 royalty financing agreements on FDA approved therapies (or those with PDUFA like $SNDX). $ASND As always, our analysis could be wrong.
swingingtech
Posted - 2 weeks ago
$NVO $ASND
https://wallstreetwaves.com/novo-nordisk-q3-outlook-can-285-million-investment-in-weight-loss-counteract-negative-market-trends
ChessGM
Posted - 2 weeks ago
$ASND Heads up alert! Only one day until Upcoming Earnings on Tuesday, 11/5/2024 Neutral (5.0) Ascendis Pharma A/S (NASDAQ: $ASND) is navigating a dynamic landscape characterized by significant strategic partnerships and ongoing clinical developments. The recent collaboration with Novo Nordisk to develop products utilizing Ascendis' innovative TransCon technology highlights a critical advance in their metabolic and cardiovascular disease portfolio. This partnership could unlock substantial revenue potential as both companies leverage their strengths—Ascendis in technology and Novo Nordisk in market reach. The company's financial metrics reveal a P/E ratio that is competitive within the biotech sector, alongside promising revenue forecasts driven by their pioneering therapies. Ascendis is positioned to capitalize on the growing demand for treatments in metabolic disorders, particularly as they move closer to potential market launches. Recent data from clinical trials, including the promising results for TransCon PTH, reinforces their strong pipeline, suggesting potential for positive EPS growth moving forward. However, the firm must navigate competitive pressures, especially from established players like BioMarin Pharmaceuticals, which are maintaining aggressive revenue targets amid Ascendis' advancements. Looking ahead, Ascendis is preparing for critical earnings reports that will likely reflect the impact of their recent strategic initiatives. Analysts are closely monitoring the consensus estimates, which anticipate growth in revenue driven by the anticipated success of their ongoing trials and new product launches. Historical performance has shown volatility in stock price reactions post-earnings announcements, underscoring the importance of meeting or exceeding expectations. With the market's current focus on growth, Ascendis’ upcoming earnings could significantly influence investor sentiment and stock performance, particularly if results align with the optimistic forecasts projected by analysts. - Funds were net buyers of $ASND during the previous reporting quarter. - Top 5 funds with large holdings in $ASND: * RA Capital Management LLC $1,379MM. CGMRank: 61% * Westfield Capital Management Company LP $677MM. CGMRank: 82% * Avoro Capital Advisors LLC $572MM. CGMRank: 85% * Adage Capital P $112MM. CGMRank: 87% * Paradigm Biocap $91MM. CGMRank: 55% - Last 10 days performance: -5% - Last 30 days performance: -16% - Last 90 days performance: -7% Follow ChessGM! Make your move and get timely earnings alerts from ChessGM. Not a financial advice.
Pika_Capital
Posted - 2 weeks ago
$ASND great collaboration today
Pika_Capital
Posted - 10/31/24
$ASND finally accumulated full position. $120 is a hell of a deal if they execute commercially on PTH successfully next year
CaptainAmrica
Posted - 10/30/24
$ASND... Dirt Cheap...In...Will probably be bought out
go43
Posted - 10/29/24
another question point blank asked $BMRN whether they're looking for royalties or plan to file a preliminary injunction against $ASND. BMRN declined to further comment on IP strategy
Estimize
Posted - 10/28/24
$ASND estimates distribution - here’s what 3 Estimize analysts are expecting $ASND to report for Q3 [Reporting 11/06 AMC]
http://www.estimi
Pika_Capital
Posted - 1 month ago
$ASND I'm fully loaded. Bring that buyout 🔥
tymtested
Posted - 1 month ago
$ASND did skytrofa sales die?
Pika_Capital
Posted - 1 month ago
$ASND will consider adding more if it gets to $120 or below. Such a no brainer after all recent developments
safeway
Posted - 1 month ago
$LLY $ASND $SRPT $NVAX very positive company. next will rally again
DonCorleone77
Posted - 09/30/24
$ASND Ascendis Pharma shares three-year results from Phase 2 PaTH Forward trial Ascendis Pharmashared 3-year results from the Company's ongoing Phase 2 PaTH Forward Trial of 57 adults with hypoparathyroidism showing that long-term treatment with TransCon PTH through Week 162 drove bone remodeling into the normal range. Deficiency of parathyroid hormone is associated with low rates of bone remodeling, accumulation of overly mature bone, and higher-than-average bone mineral density that may correspond with poorer overall bone quality compared to that seen in the general population. In contrast, these results suggest that long-term palopegteriparatide treatment promotes attainment of skeletal health parameters in line with those expected with states of parathyroid sufficiency. TransCon PTH is a prodrug of parathyroid hormone, administered once daily, designed to provide continuous exposure to released PTH over the 24-hour dosing period. Lead author Mishaela Rubin, M.D., Associate Professor of Medicine at Columbia University and an expert at the forefront of characterizing the dynamic and structural abnormalities of bone in hypoparathyroidism, shared the results in an oral presentation during ASBMR 2024, the annual meeting of the American Society for Bone & Mineral Research held in Toronto September 27-30.
tymtested
Posted - 09/26/24
$ASND So Ascendis needs $300,000,000!!???!!?? dilute dilute! and a price target of $195??????
